Skip to main content
. 2022 Mar 24;14:17588359221085232. doi: 10.1177/17588359221085232

Figure 2.

Figure 2.

Kaplan–Meier analysis of patients who received pyrotinib-based therapy after lapatinib resistance. (a) PFS of all patients who received pyrotinib-based therapy. (b) PFS of patients with brain metastases who received pyrotinib-based therapy.